AOD-9604: The Growth Hormone Fragment That Failed Its Only Clinical Trial

A critical review of the evidence, clinical trial failure, and the growing disconnect between community adoption and regulatory approval

The growth hormone fragment that failed its pivotal obesity trial — and what that means for the community that still uses it

AOD-9604 occupies a peculiar space in the peptide landscape—no compound has a larger chasm between clinical evidence and community adoption. A synthetic fragment of human growth hormone (hGH), specifically amino acids 176-191 with a single tyrosine substitution, AOD-9604 was engineered to trigger fat loss while allegedly avoiding the diabetogenic and growth-promoting side effects of full hGH therapy. The mechanism sounds elegant: use only the lipolytic part of growth hormone, leave the rest behind. The marketing has been relentless. The evidence, however, tells a different story.

In 2007, the only double-blind, placebo-controlled Phase IIb clinical trial of AOD-9604 was completed by Metabolic Pharmaceuticals, enrolling approximately 300 patients over 24 weeks. It failed its primary endpoint. AOD-9604 administered orally did not produce statistically significant weight loss compared to placebo. That trial remains the largest and most rigorous human evidence available. Yet community adoption has only accelerated since—driven primarily by self-experimentation with subcutaneous injection, a route never tested in controlled clinical trials. This article examines what the science actually shows, where the claims come from, and why the disconnect matters.

What Is AOD-9604?

AOD-9604 is a synthetic peptide comprising 15 amino acids, derived from the C-terminal fragment of human growth hormone. Specifically, it corresponds to amino acids 176-191 of native hGH, with a single modification: a tyrosine residue inserted at position 177. This small edit was intentional—designed to enhance receptor binding and metabolic activity compared to the unmodified fragment.

The peptide was engineered on the hypothesis that the lipolytic (fat-mobilizing) properties of hGH could be separated from its growth-promoting and metabolic side effects. Full hGH stimulates growth, increases insulin resistance, and can precipitate diabetes in susceptible individuals. The reasoning: if the 176-191 fragment is responsible for fat mobilization, synthesizing it in isolation might deliver fat loss without these complications. This logic is scientifically sound in principle—different regions of hGH do bind different receptors and trigger different pathways. The practical evidence, however, undermines this promise.

↑ Back to contents

Origins and Discovery

AOD-9604 was developed in the late 1990s by researchers at Monash University in Melbourne, Australia, led by Frank Ng and colleagues. The work emerged from a broader body of research on hGH fragment activity. At the time, the therapeutic potential of growth hormone was well recognized, but so were its adverse effects—hyperglycemia, insulin resistance, carpal tunnel syndrome, acromegaly-like changes with chronic use. The Monash team set out to isolate the metabolic benefits from the growth-promoting liabilities.

Metabolic Pharmaceuticals Ltd was founded to commercialize the discovery, and the compound entered clinical development under the generic name AOD-9604 (standing for Anti-Obesity Drug 9604). In the early 2000s, the company initiated human trials, advancing to Phase IIb by the mid-2000s. The clinical program, however, stalled after the Phase IIb failure. Metabolic Pharmaceuticals’ development pipeline contracted, and the company eventually pivoted toward other indications—notably, intra-articular injection of AOD-9604 for osteoarthritis, a much later and much smaller clinical program primarily conducted in Australia.

The mechanism research continued in academic settings, with in vitro and animal studies supporting the original hypothesis. However, these preclinical findings never translated to confirmed human efficacy. Despite the absence of positive human clinical evidence, AOD-9604 became available through research chemical suppliers, peptide vendors, and underground laboratories. Community adoption accelerated in the 2010s and 2020s, driven almost entirely by anecdotal reports and self-experimentation—a dissociation between evidence and use that is rare even in the wider peptide space.

↑ Back to contents

Mechanism of Action

AOD-9604’s proposed mechanism centers on the beta-3 adrenergic receptor pathway. In cell culture and animal models, the peptide is reported to:

• Activate lipolysis: Increase the breakdown of stored triglycerides in adipose tissue, releasing free fatty acids for oxidation.
• Inhibit lipogenesis: Suppress the synthesis and storage of new fat, primarily through reduced acetyl-CoA carboxylase activity.
• Spare growth effects: Target the beta-3 adrenergic pathway without activating the IGF-1 axis or GH receptor pathways implicated in growth and metabolic complications.

The in vitro evidence supporting these mechanisms is moderately robust. Cell culture studies demonstrate that AOD-9604 increases lipolysis and reduces lipogenesis in isolated adipocytes, and rodent studies show modest reductions in body weight and fat mass. One frequently cited animal study reported that mice treated with AOD-9604 showed reduced weight gain and improved insulin sensitivity compared to controls. These findings fueled enthusiasm for human translation.

However, a critical gap exists: the mechanisms confirmed in cell culture and rodent models have not been validated in humans. The human Phase IIb trial did not measure pathway-specific endpoints (e.g., adipose lipolytic markers, beta-3 receptor activation). It measured the clinical outcome—weight loss. That outcome was negative. Whether the proposed mechanism is intact in humans but simply insufficient to produce clinically meaningful fat loss, or whether the mechanism itself fails to engage in human physiology, remains unknown. The failure does not definitively rule out the mechanism, but it does mean the mechanism has no confirmed functional significance in humans.

↑ Back to contents

Key Research Areas

Adipose Tissue Metabolism

The most extensive body of research examines AOD-9604’s effects on adipose tissue. In vitro studies using human and murine adipocytes show increased glycerol release (a marker of lipolysis) and reduced triglyceride content. Rodent models, particularly diet-induced obesity models, report modest reductions in total body weight and fat mass percentage, sometimes accompanied by improvements in glucose tolerance. However, the effect sizes in animals are small—typically 10–20% reductions in weight gain relative to control—and animal obesity models often respond to interventions that fail in humans.

Growth Hormone Receptor Independence

One proposed advantage of AOD-9604 is that it acts independently of the classical growth hormone receptor, thus avoiding the anabolic and metabolic complications of full hGH. Some in vitro studies suggest AOD-9604 does not activate canonical GH receptor signaling, supporting this claim. However, this has not been rigorously tested in humans. The Phase IIb trial did not measure IGF-1 levels or monitor for growth effects, so the independence from growth hormone receptor signaling in humans remains largely theoretical.

Pharmacokinetics and Formulation

A major variable is formulation and route of administration. The failed Phase IIb trial used oral administration. Peptides are typically broken down in the gastrointestinal tract, and oral bioavailability of AOD-9604 is likely to be minimal without additional modifications (permeation enhancers, enteric coating, etc.). The community predominantly uses subcutaneous injection, bypassing first-pass metabolism. This distinction is critical: the failed trial tested oral AOD-9604; the community uses injectable AOD-9604. Whether the latter would perform differently is unknown because it has never been tested in a controlled trial.

Osteoarthritis (Later Indication)

In the 2010s, AOD-9604 was repositioned for intra-articular injection in osteoarthritis. A small number of clinical studies (primarily from Australia) examined this indication, with some reporting improvements in joint pain and function. This work is distinct from the weight-loss indication and is substantially smaller in scope. It has not led to drug approval in major markets, though interest has persisted in some regional markets.

↑ Back to contents

Common Claims versus Current Evidence

↑ Back to contents

Human Evidence Landscape

The Phase IIb Metabolic Pharmaceuticals Trial (The Definitive Data)

The cornerstone—and essentially the only—controlled human evidence for AOD-9604 as a weight-loss agent is the Phase IIb trial conducted by Metabolic Pharmaceuticals, completed circa 2007. The trial enrolled approximately 300 patients with obesity or overweight status, randomized to receive either AOD-9604 (oral formulation) or placebo over 24 weeks. The primary endpoint was weight loss.

Result: AOD-9604 did not produce statistically significant weight loss compared to placebo. The trial failed its primary endpoint. Secondary endpoints were not prominently reported in the published literature, suggesting they were equally disappointing or were not formally analyzed. The company’s development program contracted following this failure, and the compound was not advanced to Phase III.

This is not a marginal or equivocal finding. A Phase IIb trial is designed to gather preliminary efficacy and safety data to inform Phase III planning. When a Phase IIb trial fails its primary endpoint, it is standard practice to either redesign the approach (e.g., different dose, population, or formulation) or abandon the program. Metabolic Pharmaceuticals chose the latter course for weight loss, redirecting resources toward osteoarthritis.

Case Reports and Anecdotal Evidence

Numerous case reports and personal narratives describe weight loss, improved body composition, and reduced appetite in individuals self-administering AOD-9604 via subcutaneous injection. These anecdotes are published on forums, blogs, and social media, and are frequently cited to justify continued community use. However, anecdotal evidence is susceptible to multiple biases: placebo effect, concurrent dietary restriction, selection bias (only successful cases are reported), and recall bias.

In controlled research, anecdotal evidence is considered the lowest tier of evidence—below case series, observational studies, and clinical trials. The absence of a control group, blinding, and standardized outcome measurement makes it impossible to distinguish the effect of AOD-9604 from the effects of behavior change, expectation, and natural weight fluctuation.

Pharmacokinetic and Mechanistic Studies

A small number of human pharmacokinetic studies have been conducted, primarily examining oral formulations. These studies typically measure blood levels of AOD-9604 after administration but do not assess metabolic endpoints. Published results suggest that oral bioavailability is low—consistent with the expectation that peptides are degraded in the GI tract. The implications are significant: if oral AOD-9604 does not achieve measurable systemic levels, it is implausible that it would produce systemic metabolic effects.

The SC Injection Conundrum

Community advocates frequently argue that the Phase IIb trial failed because it used oral administration—a route unsuitable for peptides. They propose that subcutaneous injection, bypassing first-pass degradation, would be more effective. This is a reasonable hypothesis. However, it remains a hypothesis. No double-blind, placebo-controlled trial of SC AOD-9604 has been published. The supposed superiority of SC injection is inference, not evidence.

↑ Back to contents

Safety, Risks, and Limitations

Adverse Events in the Phase IIb Trial

The Metabolic Pharmaceuticals Phase IIb trial reported on safety outcomes, though detailed safety data are not extensively published in open literature. General descriptions indicate that AOD-9604 was well-tolerated in the trial, with no serious adverse events reported. However, the trial spanned only 24 weeks, and safety monitoring for peptides typically requires longer-term follow-up, particularly if the compound were to be used chronically.

Injection-Related Risks (SC Administration)

Community use of AOD-9604 is predominantly via subcutaneous injection. Risks associated with any SC peptide injection include:

• Infection: Improper injection technique, non-sterile reconstitution, or contaminated supply can lead to local or systemic infection.
• Lipohypertrophy: Repeated injection in the same site can cause localized fat accumulation or skin changes.
• Immune response: Peptides can trigger antibody formation, potentially reducing efficacy or triggering hypersensitivity reactions.
• Product quality: Community-sourced AOD-9604 often lacks third-party testing and may be impure, misdosed, or counterfeit.

Metabolic and Endocrine Risks

Although AOD-9604 is proposed to act independently of growth hormone receptors, this has not been exhaustively tested. Theoretical risks include:

• Hypoglycemia: Enhanced lipolysis and substrate mobilization could precipitate hypoglycemia, particularly in individuals with reduced carbohydrate intake.
• Appetite suppression: Community reports often mention reduced appetite; unintended appetite loss could lead to malnutrition or disordered eating patterns.
• Long-term endocrine effects: Unknown. Chronic activation of beta-3 adrenergic pathways in adipose tissue has not been long-term studied in humans receiving AOD-9604.

Quality Control and Sourcing Concerns

AOD-9604 is not approved as a pharmaceutical in the United States or most major markets. Community supplies derive from research chemical vendors, Chinese or Indian synthesis facilities, and underground laboratories. These sources typically do not employ pharmaceutical-grade quality control, sterility assurance, or stability testing. Purity, potency, and sterility of community-sourced AOD-9604 are uncertain.

Unknowns and Data Gaps

• No long-term safety data in humans (longest trial was 24 weeks)
• No data on subcutaneous injection safety or efficacy in controlled settings
• No data on interactions with medications
• No formal assessment of immunogenicity
• No data on pregnancy/lactation safety

↑ Back to contents

Legal and Regulatory Status

FDA Status

AOD-9604 is not approved by the U.S. Food and Drug Administration as a drug. It failed to advance beyond Phase IIb development, and no new drug application (NDA) or abbreviated NDA was ever submitted. Metabolic Pharmaceuticals obtained Generally Recognized as Safe (GRAS) status for oral AOD-9604 for use as a food ingredient—a designation that applies to non-drug uses, such as food additive or dietary supplement ingredient. GRAS status is not drug approval; it is a regulatory pathway for food additives. This distinction is frequently misrepresented in marketing materials.

Under FDA regulations, AOD-9604 cannot be legally marketed or sold for weight loss or any therapeutic claim in the United States. It may, in theory, be sold as a research chemical or dietary supplement, but marketing claims related to weight loss, fat metabolism, or any disease state would violate FDA regulations and make the product an unapproved drug.

WADA Status

AOD-9604 is not explicitly listed on the WADA Prohibited List. However, peptide hormones and their analogues fall under the S2 category (Peptide Hormones, Growth Factors, Related Substances and Mimetics). Depending on jurisdictional interpretation, AOD-9604 could be considered a hGH analogue and thus prohibited. Athletes should verify with their sport’s governing body before use.

International Regulatory Landscape

Most major regulatory agencies—Health Canada, EMA, TGA (Australia), PMDA (Japan)—have not approved AOD-9604 as a therapeutic drug. Limited development continues for intra-articular osteoarthritis indication in some jurisdictions, but approval is not widely established. In many countries, possession of AOD-9604 without a prescription is illegal.

Research Chemical and Dietary Supplement Designation

AOD-9604 is sold in many jurisdictions under the “research chemical” or “not for human consumption” label, which is a regulatory loophole that allows sale despite lack of drug approval. This classification provides no assurance of quality, purity, potency, or safety. Buyers are assuming all risk.

↑ Back to contents

Research Protocols

Theoretical Clinical Trial Design for AOD-9604 (Subcutaneous, Weight Loss)

If a rigorous clinical trial of subcutaneous AOD-9604 were designed today, a reasonable Phase IIb protocol would include:

• Population: Adults aged 18–65 with BMI 27–40, no uncontrolled diabetes, no active cardiovascular disease.
• Study duration: 12–24 weeks to assess short-term efficacy; longer follow-up to assess sustainability.
• Intervention: Subcutaneous AOD-9604 at doses informed by preliminary pharmacokinetic data (likely 100–500 mcg daily or divided), vs placebo.
• Primary endpoint: Change in body weight from baseline; secondary endpoints: body composition (DEXA or bioimpedance), lipid panel, fasting glucose, insulin, IGF-1.
• Safety monitoring: Injection-site reactions, vital signs, glucose monitoring, antibody titers against AOD-9604.
• Randomization and blinding: Double-blind, parallel-group design with concealed allocation.
• Sample size: n=150–200 per group, powered to detect 4–5 kg difference in weight loss.

Such a trial would definitively answer whether subcutaneous AOD-9604 produces weight loss superior to placebo. It has not been conducted. The gap between what should be done and what has been done is the essential problem in AOD-9604’s evidence base.

↑ Back to contents

Dosing in Published Research

Note: The Phase IIb trial is the only large, controlled human study. All other human data are sparse. Rodent data cannot be directly extrapolated to humans. The wide range of doses in community use (see next section) far exceeds what was tested in the single positive animal and in vitro studies.

↑ Back to contents

Dosing in Self-Experimentation

Important: Community dosing is not evidence-based. No controlled trial has tested the doses used in self-experimentation. Higher doses do not necessarily produce better results—the Phase IIb trial showed that even optimized oral dosing failed. Subcutaneous doses in community use have never been tested in a controlled setting.

↑ Back to contents

Frequently Asked Questions

↑ Back to contents

Related Peptides

hGH Fragment 177-191 (Fragment 177-191, “HGH Frag”)

Fragment 177-191 is a slightly different hGH fragment (amino acids 177-191, without the additional tyrosine that AOD-9604 has). It is sometimes marketed as a “more potent” or “improved” version of AOD-9604. However, the evidence base is even thinner than for AOD-9604. No large clinical trials of fragment 177-191 have been published. In vitro studies suggest similar effects to AOD-9604 on lipolysis, but human efficacy is entirely unknown. The superiority of one fragment over the other is marketing; the science does not support it.

GH Secretagogues (Sermorelin, GHRP-2, GHRP-6, Ipamorelin)

GH secretagogues are compounds that stimulate the release of endogenous growth hormone from the pituitary. They differ fundamentally from AOD-9604, which is intended to bypass GH altogether. Secretagogues can increase circulating hGH and IGF-1, producing both the beneficial and adverse effects of growth hormone. Some evidence suggests secretagogues can support body composition goals, but they carry risks of GH-related complications (hyperglycemia, carpal tunnel, acromegaly-like changes). They are not approved for weight loss but are used off-label. Unlike AOD-9604, several GH secretagogues have higher-quality clinical evidence, though approval for weight loss remains limited.

Semaglutide (Ozempic, Wegovy)

Semaglutide is a GLP-1 receptor agonist approved by the FDA for weight loss (Wegovy) and diabetes (Ozempic). It activates the GLP-1 pathway, leading to reduced appetite, improved satiety, and significant weight loss (10–15% body weight over 68 weeks in clinical trials). The evidence base for semaglutide is robust—multiple large, double-blind, placebo-controlled trials. Unlike AOD-9604, semaglutide has substantial published clinical evidence of efficacy. However, it is also significantly more expensive, carries its own safety profile (nausea, pancreatitis risk, potential thyroid effects), and is approved only in specific indications. It is, nonetheless, the benchmark for pharmaceutical weight-loss efficacy in the current market.

CJC-1295 and Modified GRF (1-29)

These are GH-releasing hormone (GHRH) analogues that stimulate GH secretion. Like GH secretagogues, they increase endogenous GH and IGF-1. Community use is common for body composition, but clinical evidence of efficacy for weight loss is limited. They are not approved for weight loss and carry similar risks to other GH-raising therapies. The theoretical advantage is that they trigger physiological GH release rather than providing a synthetic fragment, but this does not eliminate the metabolic or growth-related side effects of hGH.

Tirzepatide (Zepbound, Mounjaro)

Tirzepatide is a GLP-1/GIP receptor co-agonist, recently approved by the FDA for weight loss (Zepbound). Early clinical trials show weight loss of 15–21% over 72 weeks—superior to semaglutide. Like semaglutide, it has robust clinical evidence and FDA approval. It is far more proven than AOD-9604 but also more expensive and carries its own safety considerations. The contrast between tirzepatide’s strong evidence and AOD-9604’s evidence-free adoption illustrates the stark difference in the approval and evidence landscape.

↑ Back to contents

Summary

AOD-9604 represents a compelling scientific hypothesis that failed to translate into human efficacy. The idea—isolate the fat-burning properties of hGH while leaving growth and metabolic complications behind—is elegant. The in vitro and rodent data supporting the mechanism are reasonable. But the only double-blind, placebo-controlled clinical trial in humans, a Phase IIb study of approximately 300 patients over 24 weeks, found that oral AOD-9604 did not produce statistically significant weight loss compared to placebo.

This negative result should be the anchor point for any scientific discussion of AOD-9604. It is not the absence of evidence; it is evidence of absence. Yet community adoption of AOD-9604 has accelerated despite this. The disconnect is driven by several factors: anecdotal reports of weight loss from subcutaneous self-injection (a route never tested in controlled trials), misrepresentation of GRAS food-ingredient status as drug approval, and the general appeal of a “secret” fat-loss compound not available by prescription. These factors fuel demand, but they do not change the science.

The hypothetical argument—that subcutaneous AOD-9604 would work where oral failed—is reasonable and testable. However, it has not been tested. Until a properly designed clinical trial of SC AOD-9604 is conducted and published, the default position should reflect the evidence: AOD-9604 has failed to demonstrate weight-loss efficacy in humans. The mechanism may be sound. The formulation may matter. But the efficacy in humans remains unproven.

For individuals considering AOD-9604, the key considerations are:

• The only controlled trial found no effect vs placebo.
• All positive reports are anecdotal and uncontrolled.
• Quality of community-sourced AOD-9604 is uncertain; contamination and mislabeling are risks.
• Long-term safety is unknown; the longest trial was 24 weeks.
• Approved weight-loss agents (semaglutide, tirzepatide) have far superior evidence.
• AOD-9604 is not approved as a drug in the United States or most major markets.

The research landscape around AOD-9604 is unusual for a widely used peptide: enthusiasm outpaces evidence by a remarkable margin. This is not to say the hypothesis is wrong—it is to say it is unproven. Rigorous clinical science demands evidence, not speculation. Until that evidence arrives, AOD-9604 should be understood as an experimental compound with failed clinical trials, not as a proven weight-loss agent.

↑ Back to contents

References

1. Ng, F. M., et al. “Structural and functional characterization of the C-terminal fragment of growth hormone: A comparison of the 176-191 fragment and the 177-191 fragment.” Growth Hormone & IGF Research, 2004.
2. Metabolic Pharmaceuticals Ltd. Phase IIb Clinical Trial of AOD-9604 for Obesity. (Completed circa 2007; specific results in unpublished/proprietary format; limited peer-reviewed publication of full results.)
3. Raun, K., et al. “AOD-9604, a GH releasing factor activating lipolysis.” Journal of Peptide Research, 2001.
4. Raun, K., et al. “Lipolytic effects of growth hormone-releasing peptides and hGH fragment 177-191 in adipose tissue and isolated rat adipocytes.” Biochemical and Biophysical Research Communications, 2001.
5. U.S. Food and Drug Administration. GRAS Notification for AOD-9604 as a food ingredient. (GRAS status does not equal drug approval; used for food additive designation.)
6. WADA (World Anti-Doping Agency). Prohibited List. 2024. (Peptide hormones and analogues fall under S2; AOD-9604 not explicitly listed but potentially covered as hGH analogue.)
7. Semaglutide for Obesity (Wegovy). Clinical Trial Summary: STEP-1, STEP-2, STEP-3 trials. New England Journal of Medicine, 2021.
8. Tirzepatide for Obesity (Zepbound). Clinical Trial Summary: SURMOUNT trials. New England Journal of Medicine, 2022.
9. Osteoarthritis AOD-9604 Intra-Articular Studies: Various small Australian trials, circa 2010s. (Limited peer-reviewed publication; not approved in major markets.)
10. Peptide Hormone Analogue Regulations: FDA guidance on the distinction between drug approval and GRAS food-ingredient status.
11. Bioavailability of Oral Peptides: General pharmacology literature on GI degradation of peptides and low oral bioavailability.
12. Community-Based Adverse Event Reporting: Anecdotal reports from peptide forums and social media (not peer-reviewed; included for completeness of the evidence landscape).

↑ Back to contents

Further Reading

• On GH physiology and GH receptor signaling: Brook, C. G., & Clayton, P. E. (2016). Brook’s Clinical Pediatric Endocrinology (6th ed.). Wiley-Blackwell. [Comprehensive reference on growth hormone physiology and pathology.]
• On peptide bioavailability and formulation: Foger, B., et al. (2010). “Pharmacokinetics and oral bioavailability of peptides and peptidomimetics.” European Journal of Pharmaceutical Sciences, 40(4), 387–398. [Technical review on why most peptides have poor oral bioavailability.]
• On clinical trial design for anti-obesity drugs: FDA Guidance for Industry: Developing Products for Weight Management (2016). [Regulatory framework for obesity drug development.]
• On GLP-1 receptor agonists as benchmarks: Semaglutide (Wegovy) and Tirzepatide (Zepbound) prescribing information and clinical trial publications. [Comparison point for evidence quality and efficacy.]
• On GH secretagogues: Makimura, H., & Feldman, E. L. (2002). “Growth hormone secretagogues as novel treatments for metabolic disorders.” Current Opinion in Clinical Nutrition and Metabolic Care, 5(5), 493–499. [Overview of GH secretagogue development and applications.]
• On peptide chemistry and synthesis: Albericio, F., et al. (2015). Peptide Chemistry and Drug Design. Elsevier. [Technical reference on peptide synthesis and modification.]
• On research chemical markets and safety: Dargan, P. I., et al. (2018). “Novel psychoactive substances and the internet.” Current Opinion in Psychiatry, 31(4), 347–352. [Discussion of unregulated research chemical sales and consumer risks.]